Tech Company Financing Transactions
Eidos Therapeutics Funding Round
Eidos Therapeutics closed a $64 million Series B funding round on 4/6/2018. Backers included RA Capital, Aisling Capital and Amzak Health Investors.
Transaction Overview
Company Name
Announced On
4/6/2018
Transaction Type
Venture Equity
Amount
$64,000,000
Round
Series B
Investors
RA Capital (Lead Investor) (Rajeev Shah)
Aisling Capital (Eric Aguiar)
Proceeds Purpose
Proceeds from the financing will be used to advance Eidos' small molecule product candidate, AG10, into Phase 2 clinical trials and to continue preparations for Phase 3 clinical trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
101 Montgomery St. 2550
San Francisco, CA 94101
USA
San Francisco, CA 94101
USA
Phone
Website
Email Address
Overview
Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. Eidos seeks to treat this well-defined family of diseases at their collective source by stabilizing TTR.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Neil Kumar
Chief Financial Officer
Christine Siu
Chief Medical Officer
Jonathan Fox
Chief Scientific Officer
Uma Sinha
VP - Bus. Development
Cameron Turtle
Browse more venture capital transactions:
Prev: 4/6/2018: Thunder Token venture capital transaction
Next: 4/6/2018: Arkera venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs